• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapies and medication are ineffective. Personalized treatment could be the solution.

Cue is an intervention platform that converts passively acquired sensor data from smartphones into personalised micro-interventions for improving mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to discover their feature predictors and uncover distinct characteristics that can be used to predict changes in mood with time.

Predictors of Mood

Depression is among the most prevalent causes of mental illness.1 Yet, only half of those suffering from the condition receive treatment1. To improve the outcomes, healthcare professionals must be able to identify and treat patients with the highest likelihood of responding to specific treatments.

A customized depression treatment plan can aid. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will gain the most from specific treatments. They are using sensors for mobile phones and a voice assistant incorporating artificial intelligence as well as other digital tools. Two grants totaling more than $10 million will be used to determine biological and behavior predictors of response.

So far, the majority of research on factors that predict depression treatment effectiveness has centered on sociodemographic and clinical characteristics. These include demographics such as gender, age, and education, as well as clinical characteristics like severity of symptom, comorbidities and biological markers.

While many of these variables can be predicted by the information in medical records, very few studies have utilized longitudinal data to determine the factors that influence mood in people. Few studies also take into consideration the fact that moods can differ significantly between individuals. Therefore, it is important to devise methods that allow for the identification and quantification of personal differences between mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to create algorithms that can detect different patterns of behavior and emotions that are different between people.

The team also developed an algorithm for machine learning to model dynamic predictors for each person's mood for depression. The algorithm combines these individual differences into a unique "digital phenotype" for each participant.

The digital phenotype was associated with CAT DI scores, a psychometrically validated scale for assessing severity of symptom. However the correlation was tinny (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 1003) and varied widely among individuals.

Predictors of symptoms

Depression is one of the world's leading causes of disability1 yet it is often not properly diagnosed and treated. Depression disorders are usually not treated because of the stigma that surrounds them, as well as the lack of effective interventions.

To allow for individualized treatment, identifying factors that predict the severity of symptoms is crucial. Current prediction methods rely heavily on clinical interviews, which are unreliable and only identify a handful of characteristics that are associated with depression.

Using machine learning to combine continuous digital behavioral phenotypes that are captured by sensors on smartphones and an online mental health tracker (the Computerized Adaptive Testing Depression Inventory, the CAT-DI) with other predictors of severity of symptoms can improve the accuracy of diagnosis and the effectiveness of treatment for depression. Digital phenotypes are able to are able to capture a variety of distinct actions and behaviors that are difficult to document through interviews, and also allow for continuous, high-resolution measurements.

The study involved University of California Los Angeles (UCLA) students who were suffering from mild to severe depression symptoms. participating in the Screening and Treatment for Anxiety and Depression (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical care depending on their depression severity. Participants who scored a high on the CAT DI of 35 or 65 students were assigned online support with a coach and those with a score 75 were sent to clinics in-person for psychotherapy.

Participants were asked a set of questions at the beginning of the study concerning their demographics and psychosocial characteristics. The questions included age, sex, and education as well as financial status, marital status and whether they were divorced or not, current suicidal thoughts, intentions or attempts, as well as the frequency with which they consumed alcohol. The CAT-DI was used for assessing the severity of depression symptoms on a scale from 0-100. The CAT DI assessment was performed every two weeks for those who received online support, and weekly for those who received in-person assistance.

Predictors of magnetic treatment for depression Response

Research is focused on individualized treatment for depression. Many studies are focused on identifying predictors, which will help clinicians identify the most effective drugs to treat each individual. Particularly, pharmacogenetics can identify genetic variants that influence how the body metabolizes antidepressants. This allows doctors to select medications that are likely to work best for each patient, while minimizing the time and effort involved in trial-and-error treatments and avoid any adverse effects that could otherwise hinder progress.

Another approach that is promising is to build models for prediction using multiple data sources, including data from clinical studies and neural imaging data. These models can be used to determine the best treatment for depression combination of variables predictors of a specific outcome, such as whether or not a particular medication is likely to improve symptoms and mood. These models can be used to determine the patient's response to treatment, allowing doctors maximize the effectiveness.

A new generation uses machine learning techniques like the supervised and classification algorithms, regularized logistic regression and tree-based methods to combine the effects from multiple variables and improve predictive accuracy. These models have shown to be useful in predicting treatment outcomes such as the response to antidepressants. These models are getting more popular in psychiatry, and it is likely that they will become the norm for future clinical practice.

Research into depression's underlying mechanisms continues, in addition to predictive models based on ML. Recent research suggests that depression is connected to the dysfunctions of specific neural networks. This theory suggests that a individualized treatment for depression will be based on targeted therapies that restore normal function to these circuits.

One method of doing this is by using internet-based programs that offer a more individualized and tailored experience for patients. One study found that an internet-based program helped improve symptoms and led to a better quality life for MDD patients. A controlled, randomized study of a personalized treatment for depression revealed that a substantial percentage of patients saw improvement over time and fewer side consequences.

Predictors of side effects

In the treatment of depression one of the most difficult aspects is predicting and determining the antidepressant meds that treat depression and anxiety will cause no or minimal adverse negative effects. Many patients are prescribed various medications before finding a medication that is safe and effective. Pharmacogenetics offers a fascinating new way to take an efficient and specific approach to choosing antidepressant medications.

Several predictors may be used to determine the best antidepressant to prescribe, including genetic variants, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and comorbidities. To identify the most reliable and accurate predictors of a specific residential treatment for depression, controlled trials that are randomized with larger numbers of participants will be required. This is due to the fact that the identification of moderators or interaction effects can be a lot more difficult in trials that consider a single episode of treatment per participant instead of multiple sessions of treatment over a period of time.

In addition to that, predicting a patient's reaction will likely require information about comorbidities, symptom profiles and the patient's personal perception of effectiveness and tolerability. Presently, only a handful of easily identifiable sociodemographic and clinical variables seem to be reliable in predicting response to MDD, such as gender, age race/ethnicity BMI, the presence of alexithymia and the severity of depression symptoms.

The application of pharmacogenetics in treatment for depression treatment effectiveness is in its beginning stages and there are many hurdles to overcome. First, it is essential to have a clear understanding and definition of the genetic mechanisms that underlie depression, and a clear definition of an accurate indicator of the response to treatment. In addition, ethical concerns like privacy and the appropriate use of personal genetic information, must be considered carefully. In the long-term, pharmacogenetics may provide an opportunity to reduce the stigma associated with mental health care and improve treatment outcomes for those struggling with depression. However, as with any other psychiatric treatment, careful consideration and planning is essential. In the moment, it's best to offer patients an array of depression medications that work and encourage them to speak openly with their physicians.